| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income | 2,535 | 2,979 | 2,999 | 2,885 |
| Net loss | -14,614 | -15,429 | -15,085 | -7,586 |
| Unrealized gain on marketable securities, net of tax of 0 | 115 | 48 | 337 | 890 |
| Total other comprehensive income | 115 | 48 | 337 | 890 |
| Comprehensive loss | -14,499 | -15,381 | -14,748 | -6,696 |
| Earnings per share, basic | -0.12 | -0.13 | -0.12 | -0.11 |
| Earnings per share, diluted | -0.12 | -0.13 | -0.12 | -0.11 |
| Weighted average number of shares outstanding, basic | 122,619,311 | 122,580,967 | 122,390,303 | 71,381,731 |
| Weighted average number of shares outstanding, diluted | 122,619,311 | 122,580,967 | 122,390,303 | 71,381,731 |
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)